Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and efficacy of intradermal botulinum toxin type A for chemotherapy-induced peripheral neuropathy
IRCT20200425047202N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Aug 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of botulinum toxin type A in chemotherapy-induced peripheral neuropathy (CIPN), sponsored by Shahid Beheshti University of Medical Sciences. Started Aug 2019; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on IRCT20200425047202N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200425047202N1.